Impedimed (ASX:IPD) Debt-to-Revenue : 0.14 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Impedimed Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Impedimed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.31 Mil. Impedimed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.96 Mil. Impedimed's annualized Revenue for the quarter that ended in Dec. 2023 was A$9.40 Mil. Impedimed's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.14.

Impedimed Debt-to-Revenue Historical Data

The historical data trend for Impedimed's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Impedimed Debt-to-Revenue Chart

Impedimed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

Get a 7-Day Free Trial

0.15

0.06

0.02

0.13

Impedimed Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.03	0.02	0.12	0.13	0.14

Competitive Comparison of Impedimed's Debt-to-Revenue

For the Medical Devices subindustry, Impedimed's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Impedimed's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Impedimed's Debt-to-Revenue falls into.

Impedimed Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Impedimed's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.3	+	1.147)	/	11.249
	=	0.13

Impedimed's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.31	+	0.963)	/	9.404
	=	0.14

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Impedimed Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Impedimed's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Impedimed (ASX:IPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Impedimed Ltd (ASX:IPD) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

IPDQF:USA

Address

50 Parker Court, Unit 1, Pinkenba, QLD, AUS, 4008

Website

https://www.impedimed.com

Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates most of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The Company recognizes revenue from stand alone sale of Legacy Devices and Consumables, Sale of SOZO Device and Software Subscription Services.

Impedimed (ASX:IPD) Headlines

No Headlines